Figure 3.

Network graph for therapies of GBS. Note: Each endpoint represented a kind of therapy. Each line connecting with 2 endpoints represented there were one or more comparisons between 2 therapies. Line thicknesses correspond to the number of trials used for comparisons. (A) Trials with outcome ① of disability grade change after 4 weeks. (B) Trials with outcome ② of the rates of improvement by ≥1 grades after 4 weeks. BDNF = brain-derived neurotrophic factor, CSF filter = cerebrospinal fluid filtration, Half IVIg = 0.4 g/kg for 3 days, Half PE = half course of PE, IFNb-1α = interferon beta-1α, IVIg = intravenous immunoglobulin 0.4–0.5 g/kg daily for 4–6 days, IAPP+IVIg = immunoadsorption followed by IVIg, IAPP = immunoadsorption plasmapheresis, IVIg+eculizumab = intravenous immunoglobulin 0.4 g/kg daily for 5 days+eculizumab 900 mg once a week for 4 weeks, MTP = methylprednisolone, PbO = placebo, Pred = prednisolone, PE = plasma exchange, PE+IVIg = PE followed by IVIg, twice IVIg = 1 g/kg for 2 days, TWP = tripterygium wilfordii polyglycoside.